Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
18 de septiembre de 2018 actualizado por: Pfizer
Home Administration Of Nivestim(tm) In The Primary Prophylaxis Of Chemotherapy- Induced Febrile Neutropenia Non-interventional, Observational, Prospective Study Short Name: Home Short Name: Home
Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
De observación
Inscripción (Actual)
171
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Aschaffenburg, Alemania, 63739
- Office of Manfred Welslau
-
Aschaffenburg, Alemania, 63739
- Office of Martine Klausmann
-
Augsburg, Alemania, 86150
- Office of Bernhard Heinrich
-
Berlin, Alemania, 10117
- Campus Charite Mitte, Med. Klinik m. Schwerpunkt Haematologie und Onkologie
-
Berlin, Alemania, 13055
- Office of Reinhard Musch
-
Berlin, Alemania, 13595
- Office of Peter Klare
-
Bochum, Alemania, 44787
- Office of Ute Bückner
-
Chemnitz, Alemania, 09117
- Office of Peter Jungberg
-
Gelsenkirchen, Alemania, 45879
- Office of Ivo Azeh
-
Hannover, Alemania, 30449
- Office of Peter von Wussow
-
Heidenheim, Alemania, 89518
- Office of Volker Petersen
-
Herne, Alemania, 44623
- Office of Lars-Jörgen Hahn
-
Krefeld, Alemania, 47804
- Office of Michael Neise
-
Krefeld, Alemania, 47805
- Office of Gunther Rogmans
-
Kronach, Alemania, 96317
- Office of Peter Anhut
-
Leipzig, Alemania, 04103
- Office of Albrecht Kretzschmar
-
Leipzig, Alemania, 04107
- Office of Nidal Gazawi
-
Mannheim, Alemania, 68165
- Office of Udo Hieber
-
München, Alemania, 80638
- Office of Christoph Salat
-
Münster, Alemania, 48149
- Office of Christian Lerchenmüller
-
Oldenburg, Alemania, 26121
- Office of Burkhard Otremba
-
Osnabrück, Alemania, 49076
- Office of Julian Topaly
-
Rodgau, Alemania, 63110
- Office of Andre-Robert Rotmann
-
Scheibenberg, Alemania, 09481
- Office of Rene Schubert
-
Stolberg, Alemania, 52222
- Office of Matthias Groschek
-
Stralsund, Alemania, 18435
- Office of Carsten Hielscher
-
Stuttgart, Alemania, 70193
- Office of Thomas Kuhn
-
Wiesbaden, Alemania, 65191
- Office of Ortwin Klein
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Adults undergoing cytotoxic chemotherapy treated prophylactically with NivestimTM in order to reduce the duration of neutropenia and to reduce the incidence of chemotherapy-induced FN.
Descripción
Inclusion Criteria:
- Male and female patients ≥ 18 years
- Declaration of informed consent signed by patient
- Patients with a solid tumour or with a malignant haematological tumour
- Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle
- GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment
- Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN
Exclusion Criteria:
- Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)
- Patients who are hypersensitive to one of the excipients of NivestimTM
- Patients not undergoing chemotherapy
- Patients being treated curatively or as secondary prophylaxis with G-CSF
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Patients receiving Nivestim
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Any Significant Comorbidities
Periodo de tiempo: Baseline (Day 1)
|
Comorbidities included ongoing cardiovascular diseases, liver failure, psychological disorders, respiratory disease, viral infections and other infections (respiratory tract, systemic, uro-genital).
Percentage of participants with any ongoing comorbidities were reported in this outcome measure.
|
Baseline (Day 1)
|
|
Percentage of Participants With Different Types of Haematological Malignancies
Periodo de tiempo: Baseline (Day 1)
|
Different types of Haematological malignancies included Hodgkin's lymphoma, leukemia (chronic lymphocytic leukemia), non-Hodgkin's lymphoma and other stem cell transformations.
Percentage of participants with different type of ongoing haematological malignancies were reported in this outcome measure.
|
Baseline (Day 1)
|
|
Percentage of Participants With Different Types of Solid Tumour
Periodo de tiempo: Baseline (Day 1)
|
Different types of solid tumour included tumour of a) Digestive organs such as colon, oesophagus, pancreas, stomach tumour b) Gynaecological organs such as breast, endometrium, ovaries tumour c) Lung organs such as non-small cell lung cancer and small cell lung cancer d) Urological organs such as bladder, prostate gland, testicles tumour e) other organ tumours.
Percentage of participants with different types of ongoing solid tumour were reported in this outcome measure.
|
Baseline (Day 1)
|
|
Duration of Solid Tumour in Participants Prior to Enrolment in Study
Periodo de tiempo: Baseline (Day 1)
|
Time from diagnosis of any previous solid tumour in participants up to the enrolment in the study was recorded at baseline and reported in this outcome measure.
|
Baseline (Day 1)
|
|
Number of Participants Who Received Chemotherapy Prior to Enrolment in Study
Periodo de tiempo: Baseline (Day 1)
|
Baseline (Day 1)
|
|
|
Duration of Different Types of Chemotherapies Received by Participants During Study
Periodo de tiempo: Baseline up to 6 months
|
Baseline up to 6 months
|
|
|
Percentage of Participants With Response to Study Treatment
Periodo de tiempo: Baseline up to 6 months
|
Baseline up to 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participants' Overall Satisfaction Scores in Response to the Study Treatment
Periodo de tiempo: Baseline up to 6 months
|
Participants rated the overall satisfaction with Nivestim as part of a questionnaire.
The participants were asked to complete the questionnaire at three time points (any 3 time points during the study duration of 6 months).
The data from all the three time points was summarized and reported collectively in this outcome measure.
The satisfaction was rated on a scale ranging from 1 (minimum score) to 6 (maximum score), where higher scores indicated dissatisfaction with the treatment.
For this outcome measure, the within-participant average scores are summarized.
|
Baseline up to 6 months
|
|
Participant's Assessment for Nivestim Packaging
Periodo de tiempo: Baseline up to 6 months
|
Participants evaluated the packaging of Nivestim as part of a questionnaire.
The packaging was rated under the 2 available categories as either easy or complicated.
The participants were asked to complete the questionnaire at three time points (any 3 time points during the study duration of 6 months).
The data from all the three time points was summarized and reported collectively in this outcome measure.
For this outcome measure, the total number of participants in each answer category at at least one of the time points is displayed, that is participants who provided different ratings at the individual time points are included in more than one answer category in this summary.
|
Baseline up to 6 months
|
|
Participant's Assessment of Injection Site Pain and Tolerability
Periodo de tiempo: Baseline up to 6 months
|
Participants evaluated the injection site pain and the injection site tolerability of the treatment as part of a questionnaire.
The injection site pain was rated under the 5 available categories as: Did not feel anything, did not feel much, light stitch, painful and very painful.
Injection site tolerability was also rated under the 5 available categories as: Very good, good, satisfactory, did not tolerate well, did not tolerate at all.The participants were asked to complete the questionnaire at three time points (any 3 time points during the study duration of 6 months).
The data from all the three time points was summarized and reported collectively in this outcome measure.
For both the injection site pain and tolerability, the total number of participants in each answer category at at least one of the time points is displayed, that is participants who provided different ratings at the individual time points are included in more than one answer category for each of them.
|
Baseline up to 6 months
|
|
Participant's Assessment of Overall Tolerability of Subcutaneous Injection
Periodo de tiempo: Baseline up to 6 months
|
Participants evaluated the overall tolerability of subcutaneous injection of treatment as part of a questionnaire.
The tolerability was rated under the 5 categories as: Very good, good, satisfactory, did not tolerate well, did not tolerate at all.
The participants were asked to complete the questionnaire at three time points (any 3 time points during the study duration of 6 months).
The data from all the three time points was summarized and reported collectively in this outcome measure.
For this outcome measure, the total number of participants in each answer category at at least one of the time points is displayed, that is participants who provided different ratings at the individual time points are included in more than one answer category in this summary.
|
Baseline up to 6 months
|
|
Percentage of Participants With Neutropenia
Periodo de tiempo: Baseline up to 6 months
|
Percentage of participants with absolute neutrophil count (greater than)>0.5*10^9
Neutrophils per Liter were reported in this outcome measure.
|
Baseline up to 6 months
|
|
Percentage of Participants With at Least One Infection and Serious Infection
Periodo de tiempo: Baseline up to 6 months
|
Infections included bronchitis, upper respiratory tract infection, cystitis, herpes virus infection, influenza, lung infection, oral candidiasis, skin infection and vulvovaginal mycotic infection.
Serious Infections included serious adverse events resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to 6 months
|
|
Change From Baseline in Absolute Neutrophil Count at Cycle 1, 2, 3, 4, 5 and 6
Periodo de tiempo: Baseline, Cycle 1, 2, 3, 4, 5, 6
|
Baseline, Cycle 1, 2, 3, 4, 5, 6
|
|
|
Minimum Value of Absolute Neutrophil Count
Periodo de tiempo: Cycle 1, 2, 3, 4, 5, 6
|
Cycle 1, 2, 3, 4, 5, 6
|
|
|
Absolute Neutrophil Count at the Last Visit During Each Treatment Cycle
Periodo de tiempo: End of study visit of Cycle 1, 2, 3, 4, 5, 6 (maximum up to Month 6)
|
End of study visit of Cycle 1, 2, 3, 4, 5, 6 (maximum up to Month 6)
|
|
|
Difference Between Minimum Value of Absolute Neutrophil Count and Absolute Neutrophil Count
Periodo de tiempo: Cycle 1, 2, 3, 4, 5, 6
|
Cycle 1, 2, 3, 4, 5, 6
|
|
|
Duration From Minimum Value of Absolute Neutrophil Count to the Absolute Neutrophil Count
Periodo de tiempo: Cycle 1, 2, 3, 4, 5, 6
|
Cycle 1, 2, 3, 4, 5, 6
|
|
|
Percentage of Participants With Febrile Neutropenia
Periodo de tiempo: Baseline up to 6 months
|
Grade 3/4 febrile neutropenia is defined as a temperature of greater than or equal to (>=) 38.0 degree Celsius and absolute neutrophil count of less than (<) 1.0 × 10^9 Neutrophils per Liter.
|
Baseline up to 6 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Baseline up to 6 months
|
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship.
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; cancer; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 6 months that were absent before treatment or that worsened relative to pretreatment state.
AEs included both serious and non-serious.
|
Baseline up to 6 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
23 de septiembre de 2015
Finalización primaria (Actual)
12 de diciembre de 2016
Finalización del estudio (Actual)
12 de diciembre de 2016
Fechas de registro del estudio
Enviado por primera vez
3 de noviembre de 2016
Primero enviado que cumplió con los criterios de control de calidad
3 de noviembre de 2016
Publicado por primera vez (Estimar)
6 de noviembre de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
11 de febrero de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
18 de septiembre de 2018
Última verificación
1 de septiembre de 2018
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ZOB-NIV-1504
- C1121004 (Otro identificador: Alias Study Number)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Non-Interventional Study
-
Rutgers, The State University of New JerseyTerminadoMBSR-STEM | PMR-STEM | MBSR-NON-STEM | PMR - SIN VÁSTAGOEstados Unidos
-
Assiut UniversityDesconocidoEstudio de la NAFLD en pacientes con ERC mediante Fibroscan Study
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos